Fig. 7

Effect of 7 weeks of empagliflozin treatment of systolic BP and diastolic BP (a), heart rate (b), locomotor activity (c), and circadian rhythm during 24 h (12-h dark period and 12-h light period) of systolic BP (d), diastolic BP (e), heart rate (f), and locomotor activity (g) of SHRcp as estimated by telemetry system. Control SHRcp fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not significant. SBP systolic blood pressure; DBP diastolic blood pressure; HR heart rate. Values are mean ± SEM n = 5 in control, n = 6 in SGLT2. In a, b and c, statistical analysis was performed by two-factor ANOVA with repeated measures. In d, e, f and g, statistical analysis was performed by two-factor ANOVA followed by post hoc Tukey’s multiple comparisons test